Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience
Myeloproliferative neoplasms are characterized by a common stem cell-derived clonal proliferation, but are phenotypically diverse. JAK2 is mutated (V617F) in more than 90 % of patients with polycythemia vera (PV) and approximately 60 % of patients with essential thrombocythemia (ET) or primary myelo...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2016-10, Vol.95 (10), p.1611-1616 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1616 |
|---|---|
| container_issue | 10 |
| container_start_page | 1611 |
| container_title | Annals of hematology |
| container_volume | 95 |
| creator | Mattar, Mervat M. Morad, Mohammed Abdel Kader El Husseiny, Noha M. Ali, Noha H. El Demerdash, Doaa M. |
| description | Myeloproliferative neoplasms are characterized by a common stem cell-derived clonal proliferation, but are phenotypically diverse. JAK2 is mutated (V617F) in more than 90 % of patients with polycythemia vera (PV) and approximately 60 % of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). Pulmonary arterial hypertension (PAH) is a major complication of several hematological disorders. Chronic myeloproliferative disorders associated with PAH have been included in group five for which the etiology is unclear and/or multifactorial. The aim of this study is to screen Egyptian Philadelphia negative JAK2 positive myeloproliferative neoplasm patients for the presence of PAH and its correlation with JAK2 allele burden. We also made a review for correlation of JAK2 allele with hematological parameters comparing our results to others. We enrolled 60 patients with Philadelphia negative myeloproliferative neoplasms. All patients enrolled in the study were subjected to laboratory and imaging workup in the form of CBC, liver, kidney profile, bone marrow examination, abdominal ultrasonography, and transthoracic echocardiography. Our results revealed that 7 patients out of 60 (11.67 %) had pulmonary arterial hypertension, 3 patients with PMF, 2 patients with PRV, and 2 patients with ET, and its correlation with JAK2 allele burden was not statistically significant. Correlation analysis between JAK2 V617F allele burden and other parameters revealed: statistical significant correlation with age, HB, HCT, PLT, UA, LDH, and splenic diameter but insignificant correlation with WBCs and PAH. Pulmonary arterial hypertension prevalence in our study was 11.67 % and no significant correlation with JAK 2 allele burden. Our study is the largest one up to our knowledge that studies the association between its prevalence and JAK2 burden. |
| doi_str_mv | 10.1007/s00277-016-2765-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1811292530</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4145870251</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-9b2f7b25a02a89fdd67f540ca19862f825801216b7be9ca651f3bf1d8ef1eb223</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhS0EokPhAdggS2zYpNjOOHaWo1EpP5VgAevoJrmeceXYwU4K83x9MZymIISEN_777jlX9xDykrMLzph6mxgTShWMV4VQlSzYI7Lh21IUTOrtY7JhdVkXMq8z8iylG8a40FvxlJwJta20luWG3O1DjOhgssHTFqcfiJ5-3H0SFJxDh7SdY5-fwPd0nN0QPMQThThhtODo8TRiPvu0lC_MEQeYggsH2-XvESIMmNlEradfjtZBj248WqAeD9n0FlezMSR7fxtO6MIYg7MG4wp4DKODNKQLuvP08nAaJwue4s9sbdF3-Jw8MeASvnjYz8m3d5df9--L689XH_a766IrlZiKuhVGtUICE6Br0_eVMnLLOuC1roTRQuo8IF61qsW6g0pyU7aG9xoNx1aI8py8WXVzf99nTFMz2NShc5BbnFPDNeeiFrJkGX39D3oT5uhzd_cUk2WpVab4SnUxpBTRNGO0Qx5ww1mzJNysCTc54WZJuFmUXz0oz-2A_Z-K35FmQKxAyl_-gPEv6_-q_gILWrW8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1811053387</pqid></control><display><type>article</type><title>Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Mattar, Mervat M. ; Morad, Mohammed Abdel Kader ; El Husseiny, Noha M. ; Ali, Noha H. ; El Demerdash, Doaa M.</creator><creatorcontrib>Mattar, Mervat M. ; Morad, Mohammed Abdel Kader ; El Husseiny, Noha M. ; Ali, Noha H. ; El Demerdash, Doaa M.</creatorcontrib><description>Myeloproliferative neoplasms are characterized by a common stem cell-derived clonal proliferation, but are phenotypically diverse. JAK2 is mutated (V617F) in more than 90 % of patients with polycythemia vera (PV) and approximately 60 % of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). Pulmonary arterial hypertension (PAH) is a major complication of several hematological disorders. Chronic myeloproliferative disorders associated with PAH have been included in group five for which the etiology is unclear and/or multifactorial. The aim of this study is to screen Egyptian Philadelphia negative JAK2 positive myeloproliferative neoplasm patients for the presence of PAH and its correlation with JAK2 allele burden. We also made a review for correlation of JAK2 allele with hematological parameters comparing our results to others. We enrolled 60 patients with Philadelphia negative myeloproliferative neoplasms. All patients enrolled in the study were subjected to laboratory and imaging workup in the form of CBC, liver, kidney profile, bone marrow examination, abdominal ultrasonography, and transthoracic echocardiography. Our results revealed that 7 patients out of 60 (11.67 %) had pulmonary arterial hypertension, 3 patients with PMF, 2 patients with PRV, and 2 patients with ET, and its correlation with JAK2 allele burden was not statistically significant. Correlation analysis between JAK2 V617F allele burden and other parameters revealed: statistical significant correlation with age, HB, HCT, PLT, UA, LDH, and splenic diameter but insignificant correlation with WBCs and PAH. Pulmonary arterial hypertension prevalence in our study was 11.67 % and no significant correlation with JAK 2 allele burden. Our study is the largest one up to our knowledge that studies the association between its prevalence and JAK2 burden.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-016-2765-0</identifier><identifier>PMID: 27468853</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Alleles ; Egypt - epidemiology ; Erythrocyte Indices ; Female ; Gene Frequency ; Genetic Association Studies ; Genotype ; Hematology ; Humans ; Hypertension, Pulmonary - enzymology ; Hypertension, Pulmonary - epidemiology ; Hypertension, Pulmonary - genetics ; Janus Kinase 2 - genetics ; Leukocyte Count ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Mutation, Missense ; Myeloproliferative Disorders - blood ; Myeloproliferative Disorders - enzymology ; Myeloproliferative Disorders - epidemiology ; Myeloproliferative Disorders - genetics ; Oncology ; Original Article ; Point Mutation ; Prevalence</subject><ispartof>Annals of hematology, 2016-10, Vol.95 (10), p.1611-1616</ispartof><rights>Springer-Verlag Berlin Heidelberg 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-9b2f7b25a02a89fdd67f540ca19862f825801216b7be9ca651f3bf1d8ef1eb223</citedby><cites>FETCH-LOGICAL-c372t-9b2f7b25a02a89fdd67f540ca19862f825801216b7be9ca651f3bf1d8ef1eb223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-016-2765-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-016-2765-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27468853$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mattar, Mervat M.</creatorcontrib><creatorcontrib>Morad, Mohammed Abdel Kader</creatorcontrib><creatorcontrib>El Husseiny, Noha M.</creatorcontrib><creatorcontrib>Ali, Noha H.</creatorcontrib><creatorcontrib>El Demerdash, Doaa M.</creatorcontrib><title>Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>Myeloproliferative neoplasms are characterized by a common stem cell-derived clonal proliferation, but are phenotypically diverse. JAK2 is mutated (V617F) in more than 90 % of patients with polycythemia vera (PV) and approximately 60 % of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). Pulmonary arterial hypertension (PAH) is a major complication of several hematological disorders. Chronic myeloproliferative disorders associated with PAH have been included in group five for which the etiology is unclear and/or multifactorial. The aim of this study is to screen Egyptian Philadelphia negative JAK2 positive myeloproliferative neoplasm patients for the presence of PAH and its correlation with JAK2 allele burden. We also made a review for correlation of JAK2 allele with hematological parameters comparing our results to others. We enrolled 60 patients with Philadelphia negative myeloproliferative neoplasms. All patients enrolled in the study were subjected to laboratory and imaging workup in the form of CBC, liver, kidney profile, bone marrow examination, abdominal ultrasonography, and transthoracic echocardiography. Our results revealed that 7 patients out of 60 (11.67 %) had pulmonary arterial hypertension, 3 patients with PMF, 2 patients with PRV, and 2 patients with ET, and its correlation with JAK2 allele burden was not statistically significant. Correlation analysis between JAK2 V617F allele burden and other parameters revealed: statistical significant correlation with age, HB, HCT, PLT, UA, LDH, and splenic diameter but insignificant correlation with WBCs and PAH. Pulmonary arterial hypertension prevalence in our study was 11.67 % and no significant correlation with JAK 2 allele burden. Our study is the largest one up to our knowledge that studies the association between its prevalence and JAK2 burden.</description><subject>Adult</subject><subject>Alleles</subject><subject>Egypt - epidemiology</subject><subject>Erythrocyte Indices</subject><subject>Female</subject><subject>Gene Frequency</subject><subject>Genetic Association Studies</subject><subject>Genotype</subject><subject>Hematology</subject><subject>Humans</subject><subject>Hypertension, Pulmonary - enzymology</subject><subject>Hypertension, Pulmonary - epidemiology</subject><subject>Hypertension, Pulmonary - genetics</subject><subject>Janus Kinase 2 - genetics</subject><subject>Leukocyte Count</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mutation, Missense</subject><subject>Myeloproliferative Disorders - blood</subject><subject>Myeloproliferative Disorders - enzymology</subject><subject>Myeloproliferative Disorders - epidemiology</subject><subject>Myeloproliferative Disorders - genetics</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Point Mutation</subject><subject>Prevalence</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kc1u1DAUhS0EokPhAdggS2zYpNjOOHaWo1EpP5VgAevoJrmeceXYwU4K83x9MZymIISEN_777jlX9xDykrMLzph6mxgTShWMV4VQlSzYI7Lh21IUTOrtY7JhdVkXMq8z8iylG8a40FvxlJwJta20luWG3O1DjOhgssHTFqcfiJ5-3H0SFJxDh7SdY5-fwPd0nN0QPMQThThhtODo8TRiPvu0lC_MEQeYggsH2-XvESIMmNlEradfjtZBj248WqAeD9n0FlezMSR7fxtO6MIYg7MG4wp4DKODNKQLuvP08nAaJwue4s9sbdF3-Jw8MeASvnjYz8m3d5df9--L689XH_a766IrlZiKuhVGtUICE6Br0_eVMnLLOuC1roTRQuo8IF61qsW6g0pyU7aG9xoNx1aI8py8WXVzf99nTFMz2NShc5BbnFPDNeeiFrJkGX39D3oT5uhzd_cUk2WpVab4SnUxpBTRNGO0Qx5ww1mzJNysCTc54WZJuFmUXz0oz-2A_Z-K35FmQKxAyl_-gPEv6_-q_gILWrW8</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Mattar, Mervat M.</creator><creator>Morad, Mohammed Abdel Kader</creator><creator>El Husseiny, Noha M.</creator><creator>Ali, Noha H.</creator><creator>El Demerdash, Doaa M.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20161001</creationdate><title>Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience</title><author>Mattar, Mervat M. ; Morad, Mohammed Abdel Kader ; El Husseiny, Noha M. ; Ali, Noha H. ; El Demerdash, Doaa M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-9b2f7b25a02a89fdd67f540ca19862f825801216b7be9ca651f3bf1d8ef1eb223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Alleles</topic><topic>Egypt - epidemiology</topic><topic>Erythrocyte Indices</topic><topic>Female</topic><topic>Gene Frequency</topic><topic>Genetic Association Studies</topic><topic>Genotype</topic><topic>Hematology</topic><topic>Humans</topic><topic>Hypertension, Pulmonary - enzymology</topic><topic>Hypertension, Pulmonary - epidemiology</topic><topic>Hypertension, Pulmonary - genetics</topic><topic>Janus Kinase 2 - genetics</topic><topic>Leukocyte Count</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mutation, Missense</topic><topic>Myeloproliferative Disorders - blood</topic><topic>Myeloproliferative Disorders - enzymology</topic><topic>Myeloproliferative Disorders - epidemiology</topic><topic>Myeloproliferative Disorders - genetics</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Point Mutation</topic><topic>Prevalence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mattar, Mervat M.</creatorcontrib><creatorcontrib>Morad, Mohammed Abdel Kader</creatorcontrib><creatorcontrib>El Husseiny, Noha M.</creatorcontrib><creatorcontrib>Ali, Noha H.</creatorcontrib><creatorcontrib>El Demerdash, Doaa M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mattar, Mervat M.</au><au>Morad, Mohammed Abdel Kader</au><au>El Husseiny, Noha M.</au><au>Ali, Noha H.</au><au>El Demerdash, Doaa M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2016-10-01</date><risdate>2016</risdate><volume>95</volume><issue>10</issue><spage>1611</spage><epage>1616</epage><pages>1611-1616</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Myeloproliferative neoplasms are characterized by a common stem cell-derived clonal proliferation, but are phenotypically diverse. JAK2 is mutated (V617F) in more than 90 % of patients with polycythemia vera (PV) and approximately 60 % of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). Pulmonary arterial hypertension (PAH) is a major complication of several hematological disorders. Chronic myeloproliferative disorders associated with PAH have been included in group five for which the etiology is unclear and/or multifactorial. The aim of this study is to screen Egyptian Philadelphia negative JAK2 positive myeloproliferative neoplasm patients for the presence of PAH and its correlation with JAK2 allele burden. We also made a review for correlation of JAK2 allele with hematological parameters comparing our results to others. We enrolled 60 patients with Philadelphia negative myeloproliferative neoplasms. All patients enrolled in the study were subjected to laboratory and imaging workup in the form of CBC, liver, kidney profile, bone marrow examination, abdominal ultrasonography, and transthoracic echocardiography. Our results revealed that 7 patients out of 60 (11.67 %) had pulmonary arterial hypertension, 3 patients with PMF, 2 patients with PRV, and 2 patients with ET, and its correlation with JAK2 allele burden was not statistically significant. Correlation analysis between JAK2 V617F allele burden and other parameters revealed: statistical significant correlation with age, HB, HCT, PLT, UA, LDH, and splenic diameter but insignificant correlation with WBCs and PAH. Pulmonary arterial hypertension prevalence in our study was 11.67 % and no significant correlation with JAK 2 allele burden. Our study is the largest one up to our knowledge that studies the association between its prevalence and JAK2 burden.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>27468853</pmid><doi>10.1007/s00277-016-2765-0</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2016-10, Vol.95 (10), p.1611-1616 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1811292530 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Alleles Egypt - epidemiology Erythrocyte Indices Female Gene Frequency Genetic Association Studies Genotype Hematology Humans Hypertension, Pulmonary - enzymology Hypertension, Pulmonary - epidemiology Hypertension, Pulmonary - genetics Janus Kinase 2 - genetics Leukocyte Count Male Medicine Medicine & Public Health Middle Aged Mutation, Missense Myeloproliferative Disorders - blood Myeloproliferative Disorders - enzymology Myeloproliferative Disorders - epidemiology Myeloproliferative Disorders - genetics Oncology Original Article Point Mutation Prevalence |
| title | Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T01%3A19%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlation%20between%20JAK2%20allele%20burden%20and%20pulmonary%20arterial%20hypertension%20and%20hematological%20parameters%20in%20Philadelphia%20negative%20JAK2%20positive%20myeloproliferative%20neoplasms.%20An%20Egyptian%20experience&rft.jtitle=Annals%20of%20hematology&rft.au=Mattar,%20Mervat%20M.&rft.date=2016-10-01&rft.volume=95&rft.issue=10&rft.spage=1611&rft.epage=1616&rft.pages=1611-1616&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-016-2765-0&rft_dat=%3Cproquest_cross%3E4145870251%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1811053387&rft_id=info:pmid/27468853&rfr_iscdi=true |